Jim Cramer advises against investing in Novo Nordisk due to potential tariffs on foreign drugs. He believes it may have less of an edge compared to other pharmaceutical companies like Eli Lilly.

However, Cramer previously mentioned that Novo Nordisk became a buy at a certain yield, hinting at its potential growth. The company is actively aligning with President Trump’s goals, making it an attractive investment option.

While Novo Nordisk shows promise, other AI stocks may offer greater upside potential with lower risk. Investors interested in undervalued AI stocks that could benefit from tariffs and onshoring trends should explore other options.

For more investment insights, check out the articles on “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey’s website. No disclosures were made in this article.

Read more at Yahoo Finance: Jim Cramer Says He Does Not Want Novo Nordisk Due to Tariffs